[{"id":"64c64aba-9f59-4a50-9b06-e7fc84a016e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04282031","created_at":"2021-01-18T20:47:22.821Z","updated_at":"2024-07-02T16:35:35.330Z","phase":"Phase 1/2","brief_title":"A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT04282031","lead_sponsor":"Beta Pharma (Suzhou) Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • eciruciclib (BPI-1178)"],"overall_status":"Recruiting","enrollment":" Enrollment 224","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 03/05/2024","primary_completion_date":" 03/05/2024","study_txt":" Completion: 03/15/2024","study_completion_date":" 03/15/2024","last_update_posted":"2023-09-28"}]